Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Aridhia at the 4th Big Data Insight Group Forum


Published on

Aridhia recently presented a keynote session on the big data phenomenon and the implications for healthcare at the 4th Big Data Insight Group Forum in London, November 2012.

Published in: Health & Medicine
  • Be the first to comment

Aridhia at the 4th Big Data Insight Group Forum

  2. 2. ABOUT ARIDHIAClinically led, technology drivenFounders:Dr David Sibbald, Professor Andrew Morris,University of Dundee & NHS Scotland Focus: Integrated chronic disease management, healthcare analytics for systemAim: improvement and stratified medicineTo improve patient and public healthoutcomes by improving quality of healthservices and R&D, while driving down costs Multi-disciplinary Team: In-house team includes 60+ clinicians, computer, data & life scientists working with external Clinical Faculty
  3. 3. TACKLING HEALTHCARE & TECHNOLOGY CHALLENGES Integration and analysis of big data accelerates the ability to solve complex healthcare problems and enables stratified medicineDisease RegistryAccurate, real-time disease specific data at patient, organisational or population levelShared Care Clinical RecordConnected data solution for chronic disease management across healthcare sectorsHealthcare AnalyticsData integration and analysis for quality improvement, performance management, governance and assuranceResearch Safe HavenRepository and complex data analysis for linked, de-identified clinical, bioimage, genomic and proteomic dataPatient Self ManagementCondition specific symptom management, self-reporting, monitoring and risk stratification
  4. 4. EXPLOSION OF DIGITAL DATA 35% of all 2011 2020 digital 1.8 zettabytes data is healthcare 90 zettabytes relatedSource: IDC, Digital Universe Study, June 2012
  5. 5. Diabetes Affects 366 million CHRONIC DISEASE IMPACT 2010 annual cost: $500 billion 2030 annual cost: $6.0 trillion75% of the population has one chronic disease Cancer 13.3 million new cases/yearand 50% have two or more conditions 2010 annual cost: $290 billionPatients with a chronic disease use > 60% of 2030 annual cost: $458 billionhospital bed days Cardiovascular disease 32 million MIs & CVAs/year75% of patients admitted as medical emergencies 2010 annual cost: $863 billionhave an exacerbation of a chronic condition 2030 annual cost: $1.04 trillionThe 15% of patients with 3+ chronic conditions COPDaccount for 30% of total inpatient days Affects 210 million 2010 annual cost: $2.1 trillion10% patients account for 55% of total inpatient days 2030 annual cost: $4.8 trillion The World Economic Forum estimates that chronic diseases will cost the world economy $47 trillion over next 20 years
  6. 6. CHALLENGES TO INTEGRATED CAREFragmented services across Lack of data sharingprimary and secondary care agreementsData silos make it difficult Clinical focus on individualto assess quality of care and diseases, not multiple diseasesoutcomes across health system simultaneouslyOrganisation-centric rather than Little or no chronic diseasepatient-centric surveillanceReactive rather than proactive Data often not integrated intoclinical management national information systems
  7. 7. SYSTEM FRAGMENTATION “ chronically ill patients receive episodic care System fragmentation means that from multiple providers who rarely coordinate the care they deliver. Because of this structural deficiency, patients with chronic illnesses receive only 56 percent of clinically recommended care.” K. THORPE, ET AL: “CHRONIC CONDITIONS ACCOUNT FOR RISE IN MEDICARE SPENDING FROM 1987 TO 2006”; HEALTH AFFAIRS 29 NO. 4 (2010)
  8. 8. MAKING SENSE OF DISEASE-SPECIFIC BIG DATA WORKSScottish Care Information Diabetes Collaboration• Nationwide real-time, web-based national IT solution in support of diabetes patient and clinical activity• All 247,768 patients with type I and type II diabetes in Scotland have a SCI-DC electronic record• 8,265 of these patients have agreed to take part in research on diabetes, including clinical trials• Single care record for all 5,000+ primary, secondary and tertiary clinical care users at the point of care and 4 university research departments• Integrates data from 1,015 GP practices, 39 hospital- based diabetes clinics, 7 lab systems, national diabetic retinopathy screening system, master patient index plus multiple specialist forms & direct data entry• Patient self-management via “My Diabetes My Way” website.
  9. 9. EVIDENCE OF IMPROVED CLINICAL OUTCOMES 43% reduction in diabetic retinopathy40% reduction in amputationsSource: Diabetic Medicine 2009 Source: Diabetes Care 2008
  10. 10. JOIN THE REVOLUTION “If you live in Scotland and suffer from diabetes, you have recently been taking part in a medical revolution.” SIR MARK WALPORT, THE TIMES, MAY 2011
  11. 11. INFORMATICS CAN HELP….“..the Department [of Health] estimates that24,000 people with diabetes die prematurely eachyear because their diabetes has not beenmanaged effectively.”“An estimated 80% of the costs of diabetes in theNHS are attributable to the treatment andmanagement of avoidable diabetic complications.Fewer than one in five people with diabetes haveachieved the recommended levels for bloodglucose, blood pressure and cholesterol. Failureto carry out these simple checks heightens therisk of diabetic patients developing complications.If people develop complications they are morelikely to die early and also cost the NHS moremoney.”“…information is not being used effectively by theNHS to assess quality and improve care...”Public Accounts Committee - Seventeenth ReportDepartment of Health: The management of adult diabetes services in the NHS (22 October 2012)
  12. 12. CONSIDERATIONS: SAFETY & REGULATORYIncreasing recognition of the need for safe clinical systemsData needs to be presented in a clear, unambiguous mannerClinicians should be aware of data quality and completenessso they can make an informed decision about interpretationData should be presented in most appropriate format toavoid misinterpretationAnything that is seen as clinical decision support will requirefuture regulation – in the interests of patient safety
  13. 13. CONSIDERATIONS: CULTURAL AND PATIENT Move away from data control by clinical teams/organisations towards patients providing access to information IT companies traditionally very reluctant to share knowledge and information - need for more openness and transparency Improve bench to bedside time - need for flexible systems that can be adapted to include up to date research findings and translation into clinical care Enable patients to take more control of conditions - access to their own data; self monitoring/reporting; feedback on delivery of care Encourage end user feedback so that systems continue to meet needs
  14. 14. THE WORLD • Number of people with chronic disease will rise substantially in coming decades POPULATION IS GROWING & • Changing demographic with ageing population GETTING OLDER • Chronic disease disproportionately affects those > 60 years • Increasing prevalence of key risk factors for developing chronic disease smoking obesity alcohol lack of exerciseSource: United Nations Population Division 2011
  15. 15. STRATIFIED MEDICINE = BETTER PATIENT OUTCOMESIt will allow us to offer• The right drug Prevent premature• To the right patient deaths• For the right disease• At the right time Deliver positive experiences of care• With the right dosage Enhance quality of life for chronic• .Minimise adverse reactions disease patients .to medications Prevent avoidable harm• .Reduce the costs of clinical .trials by enabling pre-screening Enable faster .of potential trial participants and recovery .enabling the faster identification .of possible failures
  16. 16. WHERE IT ALL STARTED• In 1951 James Watson travelled from the United States to work with Francis Crick at Cambridge University• Watson and Crick used the “Model Building” approach• They physically built models out of wire, sheet metal, nuts and bolts to come up with the structure of DNA. Why did they build models? “Sometimes the fingers can grasp what the mind cannot” (Biology the Science of Life)
  17. 17. FROM TRIAL & ERROR TO PERSONALISED MEDICATIONS 100% Response Rate (%) 75% 50% 25% 0%  Treatment A  Treatment B  Treatment C Given limited ability to predict responders, doctors practice trial-and-error medicineAdapted from Vaidyanathan, Cell 2012;148:1079
  18. 18. INNOVATIVE The convergence of big data andTECHNOLOGIES life sciences enables healthcare to become truly patient-centric:MAKE THISPOSSIBLE • integrate data-intensive biology with medicine • understand clinical & genetic correlations • genomics has a network effect to catalyze changes in information technology, medicine, and society Transform health data into actionable information Support research genomics and beyond Support patient self-reporting & management Enable providers to improve patient care Build a more responsive healthcare delivery infrastructure
  19. 19. TECHNOLOGY IS THE ENABLER Single Variant(100 Snps; 103 Genotypes) Detailed Study Of Individual Genes (102 Snps; 105+ Genotypes) Regional Studies (104 Snps; 108 Genotypes ) Genome-wide Association (106 Snps; 1010 Genotypes) Complete Resequencing (108 Snps / 1012 Genotypes)
  21. 21. IS IT WORTHSTUDYINGGENETICS FORCHRONICDISEASES? Diabetes Life Time Risk 0 Parent 10% 1 Parent 30% Brother/sister 40% Both parents 70% Identical twin 80-100 %
  22. 22. WE ARE THE START OF THE GENOMICS JOURNEYCurrent Resolution Future Resolution
  23. 23. OPEN & COMPREHENSIVE COLLABORATION IS KEYIndustry • A strong scientific informatics Bioinformatics infrastructure with vibrant PHD and post doctorate communities Diagnostics Clinical Research • Academic health science centres Biotechnology with a tripartite mission and NGS significant infrastructure investment Pharmaceuticals Therapeutics • A commitment to linking information from medical and non-Academia medical sources using electronic Health Informatics patient records to support better Genetics treatment, safety and research Clinical Biostatistics • A new pathway for the regulation Skilled Workforce Training and governance of health researchGovernment • Collaborative arrangements with Healthcare Agencies the biotechnology pharmaceutical Policy Makers and medical devices industries.
  24. 24. AS COSTS DROP, WE FACE A TIDAL WAVE OF DATA Current Costs • Full genome sequence ~£3,000 [2012] • Dropping in price 10x every 2-4 years • Existing NHS genetic test ~£1,000 • Disk cost to store raw sequence ~£100 • Disk cost to store individuals variations ~10p Future Approaches • Needed for accessing, manipulating, visualizing • Requires entirely new perspective • Emergent evidence for clinical validation, clinical utility and patient stratificationHokusai, K. The Great Wave
  25. 25. NOW WE HAVE THE GENES… CLINICAL MEDICINE STRATIFIED MEDICINE Do the variants allow us to predict The right medicine to disease progression and the the right person effect of lifestyle interventions? at the right timeGENETIC EPIDEMIOLOGY MICROBIOLOGY Confirmed How does variation variants What are the pathogenichere interact with variation organisms? at other sites? PHARMACOGENETICS PHYSIOLOGY Do these variants also influence What are the physiological complication risk, or response to correlates of these variants? available treatments? EPIDEMIOLOGY What is the population risk and are there important interactions with exposures?
  26. 26. THE COMPLEX BIG DATA ENVIRONMENT OF MEDICINE High throughput screening HTA Biomarkers BRUs AHSCs Stem cells Molecular Trial Methodology pathology Cohorts Imaging Cyclotrons Biologics Preclinical models CRFs Stratification Biobanks Regulation RNAi Enabling GMP facilities technology Chemistry Genetics Technology transfer Large trials
  27. 27. INTEGRATION OF PATIENT & HETEROGENEOUS DATA Laboratory Genomic data dataE-health Record Imaging GP Hospital records admissions
  29. 29. 2011: STRATIFIED MEDICINES INNOVATION PLATFORMTechnology Strategy Board invests £5.6m in collaborative R&D projects in in partnership with “tumour profiling and data capture to improve cancer care by providing cancer specialists with information specific to the patient’s tumour which will enable more targeted treatment to be provided.” Inclusion of breast, lung, colorectal, prostate, skin & ovarian cancer patients
  30. 30. DR LUKAS WARTMAN’S STORY Lukas Wartman, 25 was finishing medical school when he was first diagnosed with acute lymphoblastic leukaemia.
  31. 31. QUESTIONS?For more information about Aridhia visit www.aridhia.comFollow us on Twitter @aridhia